2017 Fiscal Year Final Research Report
Development of a novel molecular targeted therapy against acral melanomas
Project/Area Number |
15K09760
|
Research Category |
Grant-in-Aid for Scientific Research (C)
|
Allocation Type | Multi-year Fund |
Section | 一般 |
Research Field |
Dermatology
|
Research Institution | Tokyo Medical and Dental University |
Principal Investigator |
NAMIKI Takeshi 東京医科歯科大学, 大学院医歯学総合研究科, 准教授 (50401352)
|
Co-Investigator(Kenkyū-buntansha) |
河上 裕 慶應義塾大学, 医学部(信濃町), 教授 (50161287)
|
Co-Investigator(Renkei-kenkyūsha) |
YAGUCHI Tomonori 慶應義塾大学, 医学部, 講師 (40424163)
YOKOZEKI Hiroo 東京医科歯科大学, 大学院医歯学総合研究科, 教授 (90210608)
KATAYAMA Ichiro 大阪大学, 医学研究科, 教授 (80191980)
TANEMURA Atsushi 大阪大学, 医学研究科, 講師 (50457016)
KANEKO Yasuhiko 埼玉県立がんセンター, 臨床腫瘍研究所, 統括参与 (50373387)
|
Project Period (FY) |
2015-04-01 – 2018-03-31
|
Keywords | 悪性黒色腫 / 分子標的治療 |
Outline of Final Research Achievements |
Previous studies indicate that AMP-related kinase NUAK2 participates in the proliferation and migration of melanoma cells. In this study, we identified the deletion of PTEN as a genetic aberration associated with the amplification of NUAK2. Furthermore, we showed that an increased expression of phospho-Akt(S473) was associated with NUAK2 expression. This study also showed that knockdown of NUAK2 reduces the expression of CDK2 and a CDK2 inhibitor sufficiently suppresses proliferation of NUAK2-amplified and PTEN-deleted melanoma cells.
|
Free Research Field |
悪性黒色腫
|